Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

The Benefits of Blood Money: OxyContin & Ethics

  |  Issue: March 2019  |  

Philip Seo, MD, MHSPhilip Seo, MD, MHS, is an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore. He is director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program.

References

  1. Protesters rally against Sackler family at NYC’s Met Museum. The Daily Beast.
  2. Nan Goldin. Tate Online.
  3. Golstein C. ‘It’s time, Guggenheim’: Nan Goldin launches a surprise protest at the Guggenheim museum to protest its Sackler funding. Artnet News. 2019 Feb 9.
  4. Compassion. Merriam-Webster.com. 2011.
  5. Osler W. (1925) Aequanimitas. The Student Life. P. Blakiston’s Son & Co; Philadelphia: 423.
  6. Figley CR. (1995) Compassion fatigue as secondary traumatic stress disorder: An Overview. In: Figley CR, editor. Compassion Fatigue: Coping with Secondary Traumatic Stress Disorder in Those Who Treat the Traumatized. Brunner-Routledge; New York: 1–20.
  7. Data Brief 329. Drug overdose deaths in the U.S., 1999–2017. Data table for Figure 1. Age-adjusted drug overdose death rates: U.S., 1999–2017.
  8. Overdose death rates. National Institute on Drug Abuse. 2019 Jan.
  9. Reynolds D. Overdoses now leading cause of death of Americans under 50. CBS News. 2017 Jun 6.
  10. Bursztynsky J. Americans more likely to die from opioid overdose today than car accident. CNBC. 2019 Jan 16.
  11. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990–2010: Burden of diseases, injuries, and risk factors. JAMA. 2013 Aug 14;310(6):591–608.
  12. FindLaw. Purdue Pharma v. Kentucky (11-4087-mv).
  13. Bulloch M. How oxycodone has contributed to the opioid epidemic. Pharmacy Times. 2018 Aug 2.
  14. Oxycodone and OxyContin. Med Lett Drugs Ther. 2001 Sep 17;43(1113):80–81.
  15. Van Zee A. The promotion and marketing of OxyContin: Commercial triumph, public health tragedy. Am J Public Health. 2009 Feb;99(2):221–227.
  16. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain. J Pain Symptom Manage. 2003 Nov;26(5):1026–1048.
  17. Ryan H. Congressional representatives warn WHO of OxyContin maker’s global push. LA Times. 2017 May 3.
  18. Peterson-Withorn C. Fortune of family behind OxyContin drops amid declining prescriptions. Forbes. 2016 Jun 29.

Related Articles

    Carla Guggenheim, DO, Dances through the Pain

    Two years ago, Carla Guggen­heim, DO, a rheumatologist in private practice in Lansing, Mich., was recovering from extensive shoulder surgery when her dance teacher asked her to perform a complex Indian piece from the Bharatanatyam Repertory at a gala showcasing graduate dance students. Because of her surgery, Dr. Guggenheim agreed to dance only 90 seconds…

    On Boulders & Other Projects

    The year is drawing to a close, and I have not been forced to release a statement that I am leaving The Rheumatologist “to spend more time with my family.” Once again, improbably, I have made it to the finish line. Given that, now seems to be a good time to reflect, and to give…

    U.S. Appeals Court Ruling May Clear Barrier to Generic OxyContin

    (Reuters)—A federal appeals court ruled Monday that four patents related to Purdue Pharma’s painkiller OxyContin are invalid, potentially bringing Teva Pharmaceutical Industries Ltd and others a step closer to introducing generic versions of the drug. Privately owned, Connecticut-based Purdue had sued Teva, Amneal Pharmaceuticals and Epic Pharma after they sought approval from the U.S. Food…

    New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

    (Reuters)—New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.” Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of “almost inconceivable callousness and irresponsibility, and said…